Last reviewed · How we verify
ALK fusion gene-positive non-small-cell lung cancer
Approved treatments
- Zykadia · Novartis
Zykadia blocks the activity of the ALK protein, which is involved in the growth and spread of cancer cells. - Lorbrena · Pfizer
Lorbrena works by blocking the activity of the ALK tyrosine kinase receptor, which is a protein that helps cancer cells grow. - Lorbrena · Pfizer
Lorbrena works by blocking the activity of the ALK tyrosine kinase receptor, which is a protein that helps cancer cells grow. - Lorviqua · Pfizer Inc.
As provided in real world practice
Clinical guidelines
- FDA label — 1L
LORBRENA is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. - FDA label — 1L
LORBRENA is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. - FDA label — any
ZYKADIA is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. - FDA label — 1L
LORBRENA is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. - FDA label — 1L
LORBRENA is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- ALK fusion gene-positive non-small-cell lung cancer patent landscape — cliff calendar, originator estates, attackable patents
- ALK fusion gene-positive non-small-cell lung cancer treatment landscape brief
- ALK fusion gene-positive non-small-cell lung cancer treatment updates RSS
Frequently asked questions about ALK fusion gene-positive non-small-cell lung cancer
What drugs treat ALK fusion gene-positive non-small-cell lung cancer?
Tracked treatments include Zykadia, Lorbrena, Lorviqua.
What is the treatment for ALK fusion gene-positive non-small-cell lung cancer?
Standard treatment for ALK fusion gene-positive non-small-cell lung cancer includes Zykadia, Lorbrena, Lorviqua. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for ALK fusion gene-positive non-small-cell lung cancer?
FDA label publishes guidelines for ALK fusion gene-positive non-small-cell lung cancer. 5 guideline references tracked.
Related
- Treatment landscape: ALK fusion gene-positive non-small-cell lung cancer patent cliff · ALK fusion gene-positive non-small-cell lung cancer CI report
- Treatment: Zykadia · Novartis
- Treatment: Lorbrena · Pfizer
- Treatment: Lorbrena · Pfizer
- Treatment: Lorviqua · Pfizer Inc.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing